Funded Startups in Strasbourg
Among the 15 most recent Strasbourg rounds shown, the only clearly outsized disclosed amount is SUPERBRANCHE’s $13M (2025-02-04).
Among the 15 most recent Strasbourg rounds shown, the only clearly outsized disclosed amount is SUPERBRANCHE’s $13M (2025-02-04). The next-largest disclosed figures cluster far lower—Sounduct’s $3M (2025-06-03), Nabu’s $4M (2026-03-27), Fizimed’s $4M (2025-03-13), Scalingo’s $4M (2024-07-11), and Aerleum’s $6M (2024-10-14)—so the $13M round stands apart from the rest of the disclosed set.
The list also concentrates by time and disclosure: eight of the 15 entries are dated 2025 (from 2025-01-17 through 2025-12-02), while older entries extend back to HypnoVR’s 2021-12-07 round. Sector-wise, health/healthcare appears most often (Health Care plus related items like BiPER Therapeutics and SPARTHA Medical, totaling 4 entries), and nearly a third of the rows have non-disclosed amounts (5 “Series Unknown” with undisclosed amounts, plus Cephalgo’s undisclosed $ amount on 2023-06-23).
Most recent rounds
15 shownRelated listings
Frequently asked
Which round is the biggest disclosed outlier in Strasbourg on this page, and how far above the rest is it?
SUPERBRANCHE’s $13M on 2025-02-04 is the standout: the next-highest disclosed amounts visible are $6M (Aerleum, 2024-10-14) and $4M rounds (Nabu 2026-03-27, Fizimed 2025-03-13, Scalingo 2024-07-11), with no other disclosed figure above $6M.
How concentrated are the rounds temporally among the 15 shown?
A concentration shows up in 2025: 8 of the 15 rows are dated in 2025, spanning 2025-01-17 (Kwit) through 2025-12-02 (BiPER Therapeutics). The other dates run from HypnoVR on 2021-12-07 up to the most recent entry on 2026-05-26 (WeMa, undisclosed).
Do any sectors appear disproportionately in this Strasbourg snapshot?
Health Care appears most frequently: Health Care is listed for BiPER Therapeutics (2025-12-02, $1M), Fizimed (2025-03-13, $4M), Kwit (2025-01-17, $360K), and SPARTHA Medical (2022-01-25, $3M), for 4 of 15 rows. Biotechnology also shows up multiple times (Albupad 2026-03-03, $2M; SUPERBRANCHE 2025-02-04, $13M; Dianosic 2023-02-06, $5M).
What does the disclosed-vs-undisclosed pattern look like, and does it affect comparisons?
Three rows show undisclosed amounts even though their dates are known: WeMa (2026-05-26), Cephalgo (2023-06-23), and those labeled “Series Unknown” elsewhere still generally provide amounts where not marked undisclosed (e.g., HopLunch $130K on 2026-04-01, Fizimed $4M on 2025-03-13). For magnitude comparisons, the $13M vs. the rest relies only on the disclosed $ figures.
Within the most recent 90 days on this page, which rounds are included and what size range do they cover?
Using the latest date shown (2026-05-26), the 90-day window covers HopLunch (2026-04-01, $130K), Nabu (2026-03-27, $4M), and Albupad (2026-03-03, $2M), plus WeMa (2026-05-26, undisclosed). Disclosed sizes in that window range from $130K up to $4M.
Are there stage clusters, or does the stage mix look evenly distributed across Seed and later rounds?
Stage labeling clusters around Seed and beyond: Seed appears for Nabu (2026-03-27, $4M), BiPER Therapeutics (2025-12-02, $1M), Sounduct (2025-06-03, $3M), Aerleum (2024-10-14, $6M), Dianosic (2023-02-06, $5M), SPARTHA Medical (2022-01-25, $3M), and multiple others, while Series A shows up for HypnoVR (2021-12-07, $5M) and Scalingo (2024-07-11, $4M). Several entries remain “Series Unknown” (e.g., HopLunch 2026-04-01, $130K; SUPERBRANCHE 2025-02-04, $13M), which blurs stage comparisons beyond the labeled Seed/A set.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.